Related Experiment Video

Updated: Mar 31, 2026

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

2.5K

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

L G Estévez1, E García2, M Hidalgo3

  • 1Breast Cancer Programme, Centro Integral Oncológico Clara Campal, Oña, 10, 28050, Madrid, Spain. lestevez@hmhospitales.com.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 30, 2015
PubMed

Insights

Aberrations in the phosphatidylinositol 3-kinase (PI3K) pathway are common in breast cancer. Buparlisib, a PI3K inhibitor, shows promise in preclinical and clinical studies for treating this disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Aberrant phosphatidylinositol 3-kinase (PI3K) signaling is a hallmark of many breast cancers.
  • PI3K pathway dysregulation contributes to tumor growth and progression.
  • PI3K is a critical therapeutic target in breast cancer treatment.

Purpose of the Study:

  • To review the PI3K signaling pathway and its role in breast cancer.
  • To discuss the prognostic significance of PI3K pathway mutations.
  • To evaluate the efficacy and safety of buparlisib in breast cancer.

Main Methods:

  • Literature review of PI3K pathway in breast cancer.
  • Description of buparlisib's mechanism of action as a PI3K inhibitor.
  • Summary of preclinical and clinical study findings for buparlisib.

Main Results:

  • PI3K pathway mutations have prognostic value in breast cancer.
  • Buparlisib demonstrates potent and specific PI3K inhibition.
  • Preliminary data suggest efficacy and an acceptable safety profile for buparlisib in breast cancer patients.

Conclusions:

  • PI3K pathway aberrations are crucial in breast cancer.
  • Buparlisib is a promising targeted therapy for breast cancer.
  • Further clinical investigation of buparlisib is warranted.
Keywords:
Breast cancerBuparlisibPI3K inhibitorPI3KCATargeted therapy

More Related Videos

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells11:06

Utilization of the Soft Agar Colony Formation Assay to Identify Inhibitors of Tumorigenicity in Breast Cancer Cells

Published on: May 20, 2015

30.0K
Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells09:24

Silencing of BRCA2 to Identify Novel BRCA2-regulated Biological Functions in Cultured Human Cells

Published on: August 12, 2015

9.7K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
Inhibition of CDK Activity02:34

Inhibition of CDK Activity

5.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.3K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K